ENB THERAPEUTICS

There are no approved treatments for melanoma metastatic to brain.
Many patients rapidly develop drug resistance to commonly used melanoma therapies.
A high percentage of patients do not respond at all to any approved treatments for melanoma.

Learn More

A New era in melanoma therapy

ENB Therapeutics solves these problems with pipeline drugs to treat melanoma that has spread to brain. Our therapies bypass mechanisms of drug resistance seen with other therapies. Our studies predict that the majority of patients with pigmented melanomas should respond to our therapies.

The Challenge

There are no approved treatments for melanoma metastatic to brain. Many patients rapidly develop drug resistance to commonly used melanoma therapies. A high percentage of patients do not respond at all to any approved treatments for melanoma. ENB Therapeutics wants to fill the gaps in current melanoma therapy.

Targeting the Master Switch for Melanoma

Almost 20 years ago, our team discovered that melanoma spreads through the body because a switch that should only be turned on in the developing embryo, gets turned back on in melanoma patients. This switch tells melanoma cells to leave the skin and travel to distant sites. It also tells melanoma cells to multiply continuously. Our therapies turn off this switch, stopping the melanoma cell in its tracks and causing it to die.

The Time is Right

We are developing small molecules that turn off melanoma’s master switch: The endothelin B receptor (ETBR). Our therapies have shown efficacy in preclinical studies in treating melanoma metastatic to brain and other sites in the body. We have developed a simple and cost effective screening test to help determine those most likely to respond to our treatments. It is now time to bring these agents to those in need.